Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.63 |
| ▸ | MMP13 | P45452 | 16/20 | 0.63 |
| ▸ | MMP2 | P08253 | 2/20 | 0.52 |
| ▸ | MMP3 | P08254 | 2/20 | 0.52 |
| ▸ | MMP9 | P14780 | 2/20 | 0.52 |
| ▸ | MMP8 | P22894 | 2/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | MMP14 | P50281 | 1/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696963 | 0.98 | MMP1 (0.63) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL4614895 | 0.92 | MMP1 (0.51) | MMP1MMP13RORCARBCL2L1 | |
| SCHEMBL6866682 | 0.91 | MMP1 (0.65) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL13898698 | 0.90 | MMP1 (0.49) | MMP1MMP13ARFFAR1 | |
| SCHEMBL5678202 | 0.85 | MMP1 (0.50) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6872351 | 0.84 | MMP1 (0.67) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7916340 | 0.84 | MMP1 (0.67) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6813130 | 0.83 | MMP1 (0.43) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6869740 | 0.82 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL13898717 | 0.81 | MMP1 (0.61) | MMP1MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1068180-B1 | PROCESS FOR ALKYLATING HINDERED SULFONAMIDES USEFUL IN THE PRODUCTION OF MATRIX METALLOPROTENASE INHIBITORS | PFIZER PROD INC (US) | 2004-12-15 | — | — | EP | disclosed |
| CN-1171866-C | Aryloxyarylsulfonylamino hydroxamic acid derivatives | �Ʒ� | 2004-10-20 | — | — | CN | disclosed |
| EP-1415984-A1 | Aryloxyarylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1003720-B1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-0949246-B1 | Process for preparing phenoxyphenylsulfonyl halides | PFIZER PROD INC (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-0949245-B1 | Process for alkylating hindered sulfonamides | PFIZER PROD INC (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6288246-B1 | REACTION OF HYDROXYLAMINE WITH ALKYLSILYL HALIDE, HYDROLYSIS WITH ACID | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| US-20010011143-A1 | Process for preparing phenoxyphenylsulfonyl halides | HAWKINS JOEL M (US) | 2001-08-02 | — | — | US | disclosed |
| CN-1296474-A | Alkylation of hindered sulfonamides for the preparation of matrix metalloproteinase inhibitors | PFIZER PROD INC (US) | 2001-05-23 | — | — | CN | disclosed |
| US-6229025-B1 | MICHAEL ADDITION TO PROPIOLATES | PFIZER INC | 2001-05-08 | — | — | US | disclosed |
| US-6114568-A | Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors | PFIZER INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-1003720-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| CN-1238329-A | Process for preparing phenoxyphenylsulfonyl halides | PFIZER PROD INC (US) | 1999-12-15 | — | — | CN | disclosed |
| CN-1234396-A | Process for alkylating hindered sulfonamides | PFIZER PRODUCTS CO (US) | 1999-11-10 | — | — | CN | disclosed |
| WO-1999052862-A1 | PROCESS FOR ALKYLATING HINDERED SULFONAMIDES USEFUL IN THE PRODUCTION OF MATRIX METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| CN-1232023-A | Process for preparing hydroxamic acids | PFIZER PROD INC (US) | 1999-10-20 | — | — | CN | disclosed |
| EP-0949244-A2 | Process for preparing hydroxamic acids | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0949245-A1 | Process for alkylating hindered sulfonamides | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0949246-A1 | Process for preparing phenoxyphenylsulfonyl halides | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999007675-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011143-A1 | Process for preparing phenoxyphenylsulfonyl halides | MMP2, MMP3, MMP14 | MMP1 10/4885MMP13 18/4885MMP2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.